News

A coalition is opposing the Access to Quality Diabetes Education Act of 2015, saying it limits access to care. Here's why, and how the American Association of Diabetes Educators (AADE) is responding.

A recent report evaluates the "true cost" of the 340B program. Read the key findings.

While Affordable Care Act has created huge opportunities for payers, most of those opportunities cannot be leveraged to their full advantage using 20th century strategies.

While biosimilars’ savings will not reach the historically high level achieved for small-molecule generic drugs, the impact on the healthcare industry will still be significant, according to a new report.

Joint FDA advisory committees voted 23-1 against approving Purdue Pharma’s immediate release opioid painkiller Avridi last week.

FDA has expanded approval for ticagrelor (Brilinta, AstraZeneca) to include long-term use in patients with a history of heart attack.

Next time you are looking to hire a new executive assistant, find someone with these skills and attributes

FDA approved aspirin extended release capsules (Durlaza, New Haven Pharmaceuticals, Inc.) for the prevention of stroke and acute cardiac events.

Marketing experts stress that payers and providers must find new ways to communicate with these young patients. Here's how.

Canadian study shows certain ethnic groups face higher heart disease risk factors than they did a decade ago.

Kentucky Senate Bill 192 may fund substance abuse providers to thwart heroin epidemic.

An NIH-sponsored trial enrolled more than 9,300 participants ages 50 and older with high blood pressure. View the results.

The Obama administration has proposed new regulations to include gender identity under the umbrella banning sex discrimination in healthcare. Find out what this means for health plans.

The FDA has strengthened its warning for the type 2 diabetes medicine canagliflozin (Invokana, Invokamet) related to the increased risk of bone fractures, and added new information about decreased bone mineral density.

Despite the potential benefits PAs offer, significant challenges to fully integrating them remain.

Although prescription drug misuse is declining among teens, one in two patients tested between the ages of 10 and 17 years are not using their medications appropriately, potentially putting their health at risk, according to a new analysis.

Alynlam Pharmaceuticals and The Medicines Company reported positive initial results from their ongoing Phase 1 clinical trial with their injectable cholesterol-lowing drug, ALSN-PCSsc, at the ESC Congress 2015 held in London, August 29 – September 2.

Healthcare providers, celebrities, patients and others are helping to increase awareness of idiopathic pulmonary fibrosis (IPF) during the Pulmonary Fibrosis Foundation’s (PFF) Pulmonary Fibrosis Awareness Month.

Over the last 10 years, Blue Cross Blue Shield of Michigan and stakeholders have prevented $1.4 billion in health expenses. Here's how.

The next stage of chronic care management and value-based insurance design for the continuing onslaught of high-priced specialty drugs, including PCSK9 inhibitors.

Pre-exposure prophylaxis (PrEP) may prevent HIV infection, according to a study published in Clinical Infectious Diseases. It is one of the first and largest published evaluations of the use of PrEP to prevent HIV infection in a clinical practice setting.

FDA has approved rolapitant (Varubi, Tesaro) for the prevention of chemotherapy-induced nausea and vomiting.

Rituxan (rituximab) has a consistent safety profile through multiple courses over 11 years of observation, according to a new long-term study published in the online edition of The Journal of Rheumatology.

In this commentary, attorney Nathaniel Lacktman shares why, in the era of payment reform, it is critical for health plans to provide telemedicine reimbursement.

Telemedicine is moving from a new trend to a respected form of care delivery. Here's how it is changing, and how reimbursement is evolving.

Here are seven ways to attract more millennials to your business.

The first biosimilar drug approved by FDA in March was officially launched in the United States on September 3 – at a value compared to competing medications.

A medical group in New York is rapidly shifting toward “value-based” care from fee-for-service (FFS)-spurred on by a program to reduce variations in physician practice that began by focusing on patients with diabetes.

FDA warned this week that several leading drugs for type 2 diabetes may cause severe and disabling joint pain. FDA said that sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain, and added a new Warning and Precaution about this risk to the labels of all dipeptidyl peptidase-4 (DPP-4) inhibitors.

Experts explain why more plans are getting involved in private exchanges, and share recommendations for what to do about it.